Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02581982 2023-01-10

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Phase 2 Completed

27 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03464734 2022-11-30

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Phase 2 Completed

70 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT00805129 2022-11-25

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

46 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03980041 2022-11-25

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Phase 2 Completed

49 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02500121 2022-09-30

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Phase 2 Completed

108 enrolled 15 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01524991 2022-07-11

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Phase 2 Completed

36 enrolled 12 charts

Genitourinary

Carcinoma, Transitional Cell

NCT01780545 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Phase 2 Completed

200 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Phase 2 Completed

1 enrolled

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

6 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT03051373 2021-08-09

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Phase 2 Completed

108 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Phase 2 Completed

14 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

NCT02788201 2020-11-06

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Phase 2 Completed

8 enrolled 16 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Phase 2 Completed

30 enrolled 12 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

62 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03507166 2019-08-21

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Phase 2 Completed

43 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT02109328 2019-04-11

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Phase 2 Completed

22 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01529411 2019-04-04

MAJA

Phase 2 Completed

86 enrolled

Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT02236195 2017-09-01

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Phase 2 Completed

17 enrolled

Genitourinary

Carcinoma, Transitional Cell, Rubinstein-Taybi Syndrome

NCT01828736 2017-02-06

CVH-CT02

Phase 2 Completed

61 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01328574 2017-01-13

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Phase 2 Completed

13 enrolled 15 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

NCT00683059 2016-10-17

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Phase 2 Completed

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT00588666 2016-01-22

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Phase 2 Completed

51 enrolled 7 charts

GenitourinaryMyeloid

Carcinoma, Transitional Cell, Myeloproliferative Disorders, Neoplasms

NCT01599013 2015-12-08

JASINT1

Phase 2 Completed

69 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

NCT00633789 2015-10-09

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Phase 2 Completed

597 enrolled

GastrointestinalGenitourinarySarcoma

Adenocarcinoma Of Esophagus, Carcinoma, Transitional Cell, Sarcoma

NCT01600339 2015-05-12

A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)

Phase 2 Completed

19 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT01490437 2014-09-25

PECULIAR

Phase 2 Completed

42 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT00714025 2012-01-24

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Phase 2 Completed

40 enrolled

Genitourinary

NOG-Related-Symphalangism Spectrum Disorder, Carcinoma, Transitional Cell

NCT01426126 2011-12-07

Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum

Phase 2 Completed

37 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

NCT00101608 2010-03-02

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

150 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT00077688 2009-06-04

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

44 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT00191971 2007-11-06

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Phase 2 Completed

40 enrolled

Genitourinary

Carcinoma, Transitional Cell, Urologic Neoplasms

NCT00154687 2007-07-31

Weekly TP-HDFL in the Treatment of Advanced TCC

Phase 2 Completed

40 enrolled

Genitourinary

Carcinoma, Transitional Cell

Clinical Trials

Bristol Bladder Trial

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

ABACUS

ABLE

PemCab

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

EV-201

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Neoadjuvant Atezolizumab in Localized Bladder Cancer

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

VINGEM

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Alisertib in Chemotherapy-pretreated Urothelial Cancer

MAJA

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

CVH-CT02

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

JASINT1

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)

PECULIAR

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Weekly TP-HDFL in the Treatment of Advanced TCC